Northwestern Mutual and Alex’s Lemonade Stand fund eight young investigators

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

NORTHWESTERN MUTUAL, through its foundation, will fund four young investigator grants for childhood cancer research. The awards support Alex’s Lemonade Stand Foundation’s young investigator program.

The addition of these four research projects results in eight total funded research projects this year, an $800,000 commitment. Each researcher receives a total grant of $100,000 over two-years. Four of the recipients received their initial funding last year.

The eight grant recipients are: Charalambos Kaittanis, of Memorial Sloan Kettering Cancer Center, for studying the effects of radiation therapy; Laura Schuettpelz, of Washington University at St. Louis, for harvesting bone marrow; Shizhen Zhu, of the Mayo Clinic, for neuroblastoma development; Cigall Kadoch, of Dana Farber Institute, for sarcoma tumor research; Jeffrey Huo, of The Johns Hopkins University School of Medicine, for studying the epigenetic origins of the retinoblastoma tumor-initiating cell; Carl Koschmann, of University of Michigan, for therapy for pediatric glioblastoma; Katherine Tarlock, of Fred Hutchinson Cancer Research Center, for therapeutic strategies for leukemia; and Mireya Velasquez, of Baylor College of Medicine, for research for leukemia and lymphoma.

YOU MAY BE INTERESTED IN

For nearly 25 years, business executive Lou Weisbach and urologist Richard J. Boxer have argued that finding the money to finance the cures for devastating diseases is not as difficult as it appears. To start finding the cures, the U.S. Department of the Treasury needs to issue some bonds—$750 billion worth. Next, you hire CEOs—one...

There is general agreement that the United States spends too much on health care, especially on pharmaceuticals.  But what we spend on drugs is not simply a function of price. If eggs double in price, people can simply cut the number of eggs they eat in half.  Simply stated, cost is the product of (price per unit times the number of units purchased). 
What did President Richard M. Nixon and Senator Edward M. Kennedy have in common? They each played a pivotal role in the passage of the National Cancer Act signed by Nixon on Dec. 23, 1971. The NCA established the National Cancer Program authorizing the initial investment in the NCI-designated Cancer Centers Program. 
When I first proposed targeting PCNA (proliferating cell nuclear antigen) as a therapeutic approach, the response I got was: “No one will ever make a drug against PCNA. It’s undruggable.” The protein lacks enzymatic activity, has a disordered region, and binds to over 200 other proteins within the cell. From a traditional drug development perspective, these characteristics made PCNA an impossible target.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login